Publisher Summary Although human placentas are sufficiently abundant for medical studies, they are not always suitable for purification studies. In most purification studies, researchers are not interested in the major components of the placenta—blood and connective tissue. The former gives a large volume of homogenate, and the latter makes homogenization more difficult. In addition, the human placenta is a very poor source of cellular retinoic acid-binding protein (CRABP). This chapter deals mainly with the initial treatment of placentas, an approach that provides a process improvement for large-scale preparation of relatively small molecules. Many placentas can be handled by a new extraction method planned to reduce the bulk of the homogenate. The chapter describes a new protocol that will be helpful in large-scale purifications.